Risk factors for treatment-related sensorineural hearing loss and hearing aid use in medulloblastoma patients: an observational cohort study

Fabian M. Troschel,David Rene Steike,Julian Roers,Christopher Kittel,Jan Siats,Ross Parfitt,Amélie E. Hesping,Antoinette am Zehnhoff-Dinnesen,Katrin Neumann,Hans Theodor Eich,Sergiu Scobioala
DOI: https://doi.org/10.1007/s00066-024-02308-5
2024-10-27
Strahlentherapie und Onkologie
Abstract:Purpose This study aimed to analyze treatment-related risk factors for sensorineural hearing loss (SNHL) and an indication for hearing aids (IHA) in medulloblastoma patients after craniospinal radiotherapy (CSRT) and platin-based chemotherapy (PCth). Methods A total of 58 patients (116 ears) with medulloblastoma and clinically non-relevant pre-treatment hearing thresholds were included. Cranial radiotherapy and PCth were applied sequentially according to the HIT 2000 study protocol or post-study recommendations, the NOA-07 protocol, or the PNET (primitive neuroectodermal tumor) 5 MB therapy protocol. Audiological outcomes up to a maximum post-therapeutic follow-up of 4 years were assessed. The incidence, post-treatment progression, and time-to-onset of SNHL, defined as Muenster classification grade ≥MS2b, were evaluated. Risk factors for IHA were analyzed separately. Results While 39 patients received conventionally fractionated RT (CFRT; group 1), 19 patients received hyperfractionated RT (HFRT; group 2). Over a median follow-up of 40 months, 69.2% of ears in group 1 experienced SNHL ≥MS2b compared to 89.5% in group 2 ( p = 0.017). In multivariable Cox regressions analysis, younger age and increased mean cochlear radiation dose calculated as the equivalent dose in 2‐Gy fractions (EQD2) were associated with time-to-onset of SNHL ≥MS2b ( p = 0.019 and p = 0.023, respectively) and IHA ( p < 0.001 and p = 0.016, respectively). Tomotherapy and supine positioning were associated with a lower risk for IHA in univariable modelling only ( p = 0.048 and p = 0.027, respectively). Conclusion Young age and cochlear EQD2 D mean ≥40 Gy are significant risk factors for the incidence, degree, and time-to-event of SNHL as well as for IHA in medulloblastoma patients.
oncology,radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?